Ensign Peak Advisors
RGNX icon

Ensign Peak Advisors’s Regenxbio RGNX Stock Holding History

Ensign Peak Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-72,610
Closed -$1.92M – 2130
2022
Q3 		$1.92M Buy
72,610
+4,499
+7% +$133K ﹤0.01% 797
2022
Q2 		$1.68M Buy
68,111
+46,441
+214% +$1.16M ﹤0.01% 873
2022
Q1 		$719K Hold
21,670
– – ﹤0.01% 1386
2021
Q4 		$709K Sell
21,670
-9,430
-30% -$321K ﹤0.01% 1455
2021
Q3 		$1.3M Hold
31,100
– – ﹤0.01% 1324
2021
Q2 		$1.21M Hold
31,100
– – ﹤0.01% 1367
2021
Q1 		$1.06M Hold
31,100
– – ﹤0.01% 1407
2020
Q4 		$1.41M Hold
31,100
– – ﹤0.01% 1245
2020
Q3 		$856K Hold
31,100
– – ﹤0.01% 1370
2020
Q2 		$1.15M Hold
31,100
– – ﹤0.01% 1230
2020
Q1 		$1.01M Buy
31,100
+4,400
+16% +$183K ﹤0.01% 1166
2019
Q4 		$1.09M Buy
+26,700
New +$1.05M ﹤0.01% 1300

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ensign Peak Advisors's RGNX Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 72,610 shares — an estimated $1.92M sold.

Ensign Peak Advisors first reported a position in RGNX in Q4 2019 and held it in 12 quarters. The position peaked at $1.92M in Q3 2022. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 72,610 Regenxbio shares in Q4 2022, an estimated $1.92M.
  • Ensign Peak Advisors first reported a position in Regenxbio in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's Regenxbio position peaked at $1.92M in Q3 2022.
  • 180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.